These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28950303)

  • 1. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
    Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
    Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitors-related orchitis.
    Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
    Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
    [No Abstract]   [Full Text] [Related]  

  • 3. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 4. Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
    Glutsch V; Kneitz H; Goebeler M; Gesierich A; Schilling B
    Ann Oncol; 2019 Oct; 30(10):1667-1668. PubMed ID: 31350554
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
    Riley JL
    N Engl J Med; 2013 Jul; 369(2):187-9. PubMed ID: 23724866
    [No Abstract]   [Full Text] [Related]  

  • 7. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
    Yang Y; Pei J; Gao G; Yang Z; Guo S; Yue B; Qiu J
    Oncotarget; 2016 Dec; 7(49):80855-80871. PubMed ID: 27764796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

  • 11. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
    Mehta A; Gupta A; Hannallah F; Koshy T; Reimold S
    Melanoma Res; 2016 Jun; 26(3):319-20. PubMed ID: 27110676
    [No Abstract]   [Full Text] [Related]  

  • 14. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
    Glutsch V; Kneitz H; Gesierich A; Goebeler M; Haferkamp S; Becker JC; Ugurel S; Schilling B
    Cancer Immunol Immunother; 2021 Jul; 70(7):2087-2093. PubMed ID: 33439294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
    Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP
    Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.
    Hoogland AI; Brohl AS; Small BJ; Michael L; Wuthrick E; Eroglu Z; Blakaj D; Verschraegen C; Khushalani NI; Jim HSL; Kim S
    Cancer Med; 2024 Jul; 13(14):e7464. PubMed ID: 39021272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.